UK BioTech Thalia Therapeutics raises €3.1 million and acquires Sanmirna Therapeutics | EU-Startups

▤ Summary

Thalia Therapeutics has raised €3.1 million and acquired Sanmirna Therapeutics to accelerate its RNA therapeutics strategy. The deal adds miRisten, a clinical-stage microRNA candidate for acute myeloid leukemia, and moves Thalia closer to becoming a clinical-stage oncology company. The company plans to use most of the new capital to complete Phase 1 development, advance cardiovascular assets toward IND status, and support working capital and R&D. The acquisition also brings a new therapeutic modality into Thalia’s pipeline and broadens its portfolio across oncology and cardiovascular disease.

▦ Linked Companies